Back
BridgeBio Pharma Inc (BBIO)
BiotechnologyBBIO · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$65.34
+0.55%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-3.79
ROE
Gross margin
95.1%
Debt/Equity
Revenue growth
66.8%
P/B ratio
Beta
Forward P/E
BridgeBio Pharma Inc — company intelligence
Earnings surprises
Q2 2026$-0.78 vs $-0.60 est-31.1%
Q1 2026$-0.84 vs $-0.69 est-21.4%
Q4 2025$-1.00 vs $-0.76 est-32.1%
Q3 2025$-0.95 vs $-0.91 est-4.8%
Analyst consensus · 29 analysts
26 Buy3 Hold0 Sell
Updated Oct 9, 2026
Insider activity · 90 days
0 buys1 sellnet -2,000 shares
Apuli MaricelSell 2,000 · Jul 30, 2026
Recent SEC filings
4 — Insider transaction reportSep 21, 2026
8-K — Material event reportAug 31, 2026
4 — Insider transaction reportAug 20, 2026
Latest news
BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript — SeekingAlpha · 3w ago
BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript — SeekingAlpha · Sep 10, 2026
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target — Benzinga · Sep 10, 2026
BridgeBio Pharma, Inc. (BBIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript — SeekingAlpha · Sep 9, 2026
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.